ATM/ATR
Ataxia telangiectasia mutated; ATM and RAD3 related
ATM/ATR, members of the phosphatidyl inositol 3-kinase-like family of serine/threonine protein kinases (PIKKs), are widely known as being central players in the mitotic DNA damage response (DDR), mounting responses to DNA double-strand breaks (DSBs) and single-stranded DNA (ssDNA) respectively. Activation of ATM by ionizing radiation results in the activation of signal transduction pathways that induce cell cycle arrest at G1/S, S and G2/M. ATR is required for cell cycle arrest in response to DNA-damaging agents such as ultraviolet radiation that cause bulky lesions.
Upon activation, ATM/ATR phosphorylate numerous targets to stabilize stalled replication forks, repair damaged DNA, and inhibit cell cycle progression to ensure survival of the cell and safeguard integrity of the genome. ATM and ATR are central players in activating cell cycle checkpoints and function as an active barrier against genome instability and tumorigenesis in replicating cells.
ATM/ATR Isoform Specific Products
All Product Categories
-
ATM/ATR Related Products (121)
Related Products (121)
-
Antibodies (7)
-
ATM/ATR Isoform Comparison
-
ATR-IN-23
0 ImagesCat. No.: HY-149952CAS No.: 2923800-62-6ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers.
-
ATM Inhibitor-7
0 ImagesCat. No.: HY-149291CAS No.: 3033712-80-7
-
ATM Inhibitor-4
0 ImagesCat. No.: HY-144687CAS No.: 2769140-74-9
-
ICT10336
0 ImagesCat. No.: HY-161838ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit ATR activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.
-
AZD-7648 (GMP)
0 ImagesCat. No.: HY-111783GCAS No.: 2230820-11-6AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity.
-
ATM Inhibitor-11
0 ImagesCat. No.: HY-169310CAS No.: 2878473-51-7ATM Inhibitor-11 (Compound 1) is an inhibitor for ATM with an IC50 of 0.32 nM. ATM Inhibitor-11 inhibits the KAP1 phosphorylation with an IC50 of 0.97 nM. ATM Inhibitor-11 exhibits high exposure in the brain, heart and plasma of ICR mouse. ATM Inhibitor-11 exhibits anti-tumor efficacy in NCI-H441 xenograft mouse model.
-
Gartisertib-d8
0 ImagesCat. No.: HY-136270SCAS No.: 1792214-00-6Synonyms: VX-803-d8; M4344-d8; ATR inhibitor 2-d8Gartisertib-d8 (VX-803-d8) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity.
-
ATR ligand 2
0 ImagesCat. No.: HY-182017CAS No.: 3060178-60-8
-
Murabutide
0 ImagesCat. No.: HY-106055CAS No.: 74817-61-1Murabutide is an immunomodulator and also a NOD2 receptor agonist. Murabutide enhances the signal transduction of ATR and NOD2, mediates the activation of the DDR pathway, and thereby repairs radiation-induced DNA double-strand breaks. Murabutide inhibits radiation-induced cell apoptosis and protects cells and mice from radiation-induced toxic damage. Murabutide induces the expression and DNA-binding activity of Oct-1 in macrophages, thereby inhibiting the transcription and replication of HIV-1. Murabutide reduces the expression levels of CD4 and CCR5 on the surface of macrophages, and induces the secretion of β-chemokines, TNF-α and IL-6. Murabutide enhances non-specific viral resistance and targets reticuloendothelial cells. Murabutide can be used in research related to radiation-induced damage and human immunodeficiency virus type 1 infection.
-
ATR-IN-10
0 ImagesCat. No.: HY-144214CAS No.: 2713577-93-4ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC50 value of 2.978 μM.
-
ATR-IN-32
0 ImagesCat. No.: HY-171745CAS No.: 2902715-97-1ATR-IN-32 is an orally active ATR inhibitor. ATR-IN-32 potently inhibits the proliferation of MIA PaCa-2 cells. ATR-IN-32 exerts significant tumor growth inhibition in mice bearing LOVO and HT-29 xenografts. ATR-IN-32 can be used for the study of cancers mediated by ATR protein kinase, such as colorectal cancer, pancreatic cancer.
-
ATR-IN-19
0 ImagesCat. No.: HY-147190CAS No.: 2648989-61-9ATR-IN-19 (Compound 15 R-configure) is an ATR inhibitor.
-
ATM-IN-1
0 ImagesCat. No.: HY-142931CAS No.: 2662761-76-2ATM-IN-1 is a potent inhibitor of ATM. ATM is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3).
-
ATR-IN-21
0 ImagesCat. No.: HY-153393CAS No.: 2905312-17-4ATR-IN-21 (compound 60) is a potent ATR inhibitor with an IC50 value of <1000 nM.
